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Altering physical properties of pharmaceutical co-
crystals in a systematic manner 
 
Christer B. Aakeröy,* Safiyyah Forbes, and John Desper 
  
Systematic structure-property studies on a series of co-crystals of potential cancer drugs with 
aliphatic dicarboxylic acids were undertaken. This study reveals that systematic changes to the 
molecular nature of the co-crystallizing agent combined with control over the way individual 
building blocks are organized within the crystalline lattice makes it possible to establish 
predictable links between molecular structure and macroscopic physical properties, such as 
melting behaviour and aqueous solubility.  However, it is not possible to find any notable 
correlation between physical properties-chemical compositions in the absence of structural 
consistency.  
 
 
Introduction 
Active pharmaceutical ingredients (APIs) can exist in a variety of 
distinct crystalline forms, where each form may display unique 
properties such as morphology, hygroscopicity, thermal stability, 
and solubility, all of which can be critical during formulation and for 
delivery and efficacy.1 Crystal engineering principles2 have been 
applied as a way of tailoring the physicochemical properties (i.e. 
melting point, solubility, dissolution rate and bioavailability) of 
APIs.3,4,5,6 In an earlier systematic study, we have reported that the 
melting behavior and solubility of N,N'-bis(4-pyridinecarboxamide)-
1,6-hexane can be altered in a controllable manner without making 
or breaking covalent bonds.7 
Altering the interactions between molecules can obviously 
have direct impact on the properties of the solid form of that 
particular compound,8 and co-crystals of pharmaceuticals can 
therefore achieve greater stability (shelf-life), bioavailability, 
solubility and enhanced potency compared to the APIs by 
themselves.9 However, it is still difficult to predict how the 
physical properties will be different with respect to the 
corresponding properties of the pure homomeric solids.  To 
facilitate the preparation of new crystalline forms where we 
may be able to ‘dial-in’ some bulk behavior of a new solid form 
of an API, it would be very helpful to have access to synthetic 
protocols based on intermolecular interactions that can identify 
precise molecular recognition events that are likely to take 
place between a given API and a suitable co-crystallizing 
agent.10  In addition, in order to be able to systematically vary 
properties, it is essential to have considerable control over the 
metrics of the resulting crystal structures. 
 Previous work with bis(pyridinecarboxamido)alkanes (Ia,b 
and II) Scheme I, shows that self-complementary 
amide…amide N-H…O hydrogen bonds dominate the solid-
state structures of such molecules, even in the presence of a 
potentially competitive hydrogen-bond acceptor such as a 
pyridyl moiety.11 These compounds are of pharmaceutical 
interest because the methylene bis-acetamide derivatives 
present in these APIs have been shown to be effective inducers 
of apoptosis of several cell lines.12 Moreover, the addition of a 
pyridyl moiety to the bis-acetamides has produced compounds 
capable of inhibiting the proliferation of lung cancer cells.13 
 Unfortunately, these compounds display poor aqueous 
solubility, which ultimately limits their usefulness and 
potential. We therefore set out to combine several of these 
molecules with inherently more soluble co-crystallizing agents 
with a view to enhancing the overall solubility of the API 
without interfering with its molecular structure.  As co-
crystallizing agents we opted for dicarboxylic acids because 
such compounds, ranging from succinic to dodecanedioic acid, 
are generally regarded as safe by the FDA.14 We can also use 
the well-established COOH...N(py), O-H...N based synthon for 
driving the co-crystal synthesis in each case,15 Scheme 1. The 
combination of diacids with bis-pyridine building blocks is 
expected to produce infinite 1-D chains, and the amide moiety 
(which prefers a self-complementary N-H...O hydrogen bond 
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over an N-H...N(py) interaction) can provide a cross-link 
between neighbouring chains, thus creating a 2-D assembly. 
   
 
 
 
Scheme 1  Bis(pyridinecarboxamido) alkane molecules (Ia, Ib and IIa) with 
expected primary acid…pyridine synthons (I-II). The N-H hydrogen-bond 
donor with the amide C=O (III). 
The more structural control we can maintain upon moving 
through the series of dicarboxylic acids, the more likely it is 
that any physical property will change in a predictable manner. 
Modification of melting behavior and solubility plays a vital role in 
the development and formulation of APIs, and the rationale behind 
our approach to modulating properties through systematic co-crystal 
synthesis is readily illustrated by examining the melting points of 
even-chain aliphatic dicarboxylic acids as a function of carbon atom 
chain length, Figure 1.16 As long as the crystal structures remain 
more or less the same (the even-chain acids pack in very similar 
ways),there is a reasonable correlation between molecular structure 
(chain length in this case) and melting point, however as soon as we 
add an odd-chain acid into the series (which packs in a very different 
manner), the correlation is absent, Figure 1. 
 
 
 
 
 
Figure 1 Melting points of aliphatic even chain (C4-C12) dicarboxylic 
acids plotted against the number of carbon atoms in each acid.  
 
The take-home message from this is that in order to ‘dial-in’ 
physical properties, it is clear that (a) the nature of the 
individual building blocks matters and (b) the crystal structure 
matters.  The goals of this study, therefore are (i) to establish 
structural consistency in a series of co-crystals driven by 
COOH...N(py) hydrogen bonds; (ii) to determine the sensitivity 
of the supramolecular synthesis to changes in molecular 
geometry of the API and/or co-crystallizing agent (the primary 
recognition sites will remain intact) and (iii) to establish if 
physical properties can be related in some ways to the 
molecular structure of the co-crystallizing agent. 
 
Experimental 
All chemicals were purchased from Aldrich or Acros Organics and 
used without further purification.  Melting points were determined 
on a Gallenkamp melting point apparatus and are uncorrected. 
Compounds were prepared for infrared spectroscopic (IR) analysis 
as a mixture in KBr and ZnSe ATR crystal. 
Synthetic procedures  
Compounds Ia, N,N'-bis(4-pyridinecarboxamide)-1,4-butane; 
Ib, N,N'-bis(4-pyridinecarboxamide)-1,8-octane; IIa, N,N'-
bis(3-pyridinecarboxamide)-1,6-hexane; were synthesized and 
characterized according to previously reported methods.17  Each 
compound was subsequently co-crystallized with five different 
aliphatic diacids, Fig 2 (inset).  Fifteen co-crystals were 
obtained, eleven of which produced crystal of sufficient quality 
to allow for single-crystal structure determination. 
 
Synthesis of N,N'-bis(4-pyridinecarboxamide)-1,4-butane  
adipic acid (1:1), 1. N,N’-bis(4-pyridinecarboxamide)-1,4-
butane Ia (0.015 g, 0.053 mmol)  was dissolved in 4 mL of 
ethanol-nitromethane (1:1) to which adipic acid (0.007 g, 0.053 
mmol) in  4 mL of ethanol-nitromethane (1:1) was added and 
allowed to evaporate at room temperature. Gold prisms were 
obtained after five days. Mp 201-203 oC; (ZnSe ATR crystal) ν 
2537 cm-1, 1871 cm-1(O-H…N, br), 3382 cm-1 (N-H amide), 
1699 cm-1 (C=O, acid, s), 1622 cm-1 (C=O, amide, s). 
 
Synthesis of N,N'-bis(4-pyridinecarboxamide)-1,4-butane  
suberic acid (1:1), 2. N,N’-bis(4-pyridinecarboxamide)-1,4-
butane Ia (0.015 g, 0.053 mmol)  was dissolved in 4 mL of 
ethanol-nitromethane (1:1) to which a solution of suberic acid 
(0.009 g, 0.053 mmol) in  4 mL of ethanol-nitromethane (1:1) 
was added and allowed to stand at room temperature to undergo 
slow evaporation. Colorless plates were obtained after ten days. 
Mp 196-198 oC; (ZnSe ATR crystal) ν 2500 cm-1, 1875 cm-1(O-
H…N, br), 3313 cm-1 (N-H amide), 1703 cm-1 (C=O, acid, s), 
1629 cm-1 (C=O, amide, s). 
 
Synthesis of N,N'-bis(4-pyridinecarboxamide)-1,8-octane 
succinic acid (1:1), 3. A solution of N,N’-bis(4-
pyridinecarboxamide)-1,8-octane Ib (0.02 g, 0.056 mmol) in 5 
mL ethanol was mixed with a solution of succinic acid (0.007g, 
0.056 mmol) in 5 mL of ethanol and was allowed to stand to 
slowly evaporate. Colorless plates were obtained after ten days. 
Mp: 185-187 oC; (KBr pellet) ν 2495 cm-1, 1920 cm-1 (O-H...N, 
br), 3309 cm-1 (NH amide), 1704 cm-1 (C=O acid, s), 1630 cm-1 
(C=O amide, s). 
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Synthesis of N,N'-bis(4-pyridinecarboxamide)-1,8-octane 
adipic acid (1:1), 4. A solution of N,N'-bis(4-
pyridinecarboxamide)-1,8-octane Ib (0.02 g, 0.056 mmol) in 5 
mL ethanol was mixed with a solution of adipic acid (0.008 g, 
0.056 mmol) in 5 mL of ethanol and was allowed to stand for 
slow evaporation. Colorless plates were obtained after fifteen 
days. Mp 160-162 oC; KBr pellet) ν 2500 cm-1, 1922 cm-1 (O-
H...N, br), 3320 cm-1 (NH amide), 1710cm-1 (C=O acid, s), 1638 
cm-1 (C=O amide, s). 
 
Synthesis of N,N'-bis(4-pyridinecarboxamide)-1,8-octane 
suberic acid (1:1), 5.  N,N'-bis(4-pyridinecarboxamide)-1,8-
octane Ib (0.02 g, 0.056 mmol) was dissolved in 5 mL of 
ethanol. To this solution was added suberic acid (0.009, 0.056 
mmol) in 5 mL of ethanol.  The resulting solution was allowed 
to stand at room temperature for slow evaporation. Colorless 
prisms were obtained after twenty days. Mp 163-165 oC; (KBr 
pellet) ν 2501 cm-1, 1892 cm-1 (O-H...N, br), 3317 cm-1 (NH 
amide), 1706 cm-1 (C=O acid, s), 1635 cm-1  (C=O amide, s). 
 
Synthesis of N,N'-bis(4-pyridinecarboxamide)-1,8-octane 
sebacic acid (1:1), 6. N,N’-bis(4-pyridinecarboxamide)-1,8-
octane Ib (0.015 g, 0.0423 mmol)  was dissolved in 4 mL of 
ethanol-nitromethane (1:1) to which a solution of sebacic acid 
(0.009 g, 0.0423 mmol) in  4 mL of ethanol-nitromethane (1:1) 
was added and allowed to stand at room temperature for slow 
evaporation. Colorless plates were obtained after two weeks.  
Mp 162-163 oC; (ZnSe ATR crystal) ν 2520 cm-1, 1871 cm-1(O-
H…N, br), 3322 cm-1 (N-H amide), 1699 cm-1 (C=O, acid, s), 
1631 cm-1 (C=O, amide, s). 
 
Synthesis of N,N'-bis(3-pyridinecarboxamide)-1,6-hexane 
succinic acid (1:1), 7. A solution of N,N'-bis(3-
pyridinecarboxamide)-1,6-hexane II (0.02 g, 0.061 mmol) in 
8mL acetonitrile-ethyl acetate (1:1)  was mixed a solution of 
succinic acid (0.007 g, 0.061 mmol) in 2 mL of acetonitrile-
ethyl acetate (1:1) and was allowed to stand at room 
temperature for slow evaporation.  Colorless prisms were 
obtained after ten days. Mp 147-148 oC ; IR (KBr pellet) ν 2481 
cm-1, 1924 cm-1 (O-H…N, br), 3309 cm-1 (N-H amide), 1690 
cm-1 (C=O, acid, s), 1637 cm-1 (C=O, amide, s). 
 
Synthesis of N,N'-bis(3-pyridinecarboxamide)-1,6-hexane 
adipic acid (1:1), 8. N,N'-bis(3-pyridinecarboxamide)-1,6-
hexane II (0.015 g, 0.046 mmol) was dissolved in 2 mL of 
ethanol-nitromethane (1:1) and adipic acid (0.007 g, 0.046 
mmol) in 2 mL ethanol-nitromethane (1:1). The resulting 
solution was gently heated and left at room temperature for 
slow evaporation. After twenty days, colorless needles were 
obtained. Mp: 166-168 oC; (ZnSe ATR crystal) ν 2516 cm-1, 
1895 cm-1 (O-H…N, br), 3309 cm-1 (N-H, amide), 1695 cm-1 
(C=O acid, s), 1629 cm-1 (C=O amide, s). 
 
Synthesis of N,N'-bis(3-pyridinecarboxamide)-1,6-hexane 
suberic acid (1:1), 9. N,N'-bis(3-pyridinecarboxamide)-1,6-
hexane II (0.015 g, 0.046 mmol) was dissolved in 10 mL 
nitromethane-ethylacetate (1:1) and mixed with a solution of 
suberic acid (0.008 g, 0.046 mmol) in 5 mL of nitromethane- 
ethyl acetate (1:1). The resulting solution was heated and 
allowed to stand at ambient temperature for slow evaporation. 
Colorless plates were obtained after four days. Mp 182-184 oC;  
(ZnSe ATR crystal) ν 2496 cm-1, 1896 cm-1 (O-H….N, br), 3329 
cm-1 (NH  amide), 1701 cm-1 (C=O acid, s), 1627 cm-1 (C=O, 
amide, s). 
 
Synthesis of N,N'-bis(3-pyridinecarboxamide)-1,6-hexane 
sebacic acid (1:1), 10. N,N'-bis(3-pyridinecarboxamide)-1,6-
hexane II (0.05 g, 0.14mmol) was dissolved in 10mL 
nitromethane-ethyl acetate (1:1) and mixed with a solution of 
sebacic acid (0.028 g, 0.14 mmol) in 5mL nitromethane- ethyl 
acetate (1:1). The resulting solution was heated and allowed to 
stand at ambient temperature for slow evaporation. Colorless 
rods were obtained after ten days. Mp 180-181 oC; (KBr pellet) 
ν 2508 cm-1, 1905 cm-1 (O-H….N, br), 3305 cm-1 (NH  amide), 
1700 cm-1 (C=O acid, s), 1637 cm-1 (C=O, amide, s). 
 
Synthesis of N,N'-bis(3-pyridinecarboxamide)-1,6-hexane 
dodecanedioic acid (1:1), 11. N,N'-bis(3-
pyridinecarboxamide)-1,6-hexane II (0.015 g, 0.046 mmol) was  
dissolved in 10 mL nitromethane-ethylacetate (1:1) and mixed 
with a solution of dodecanedioic acid (0.011 g, 0.046 mmol) in 
5 mL of nitromethane- ethyl acetate (1:1). The resulting 
solution was heated and allowed to stand at ambient 
temperature for slow evaporation.  Colorless needles were 
obtained after five days. Mp 160-162 oC; (ZnSe ATR crystal) ν 
2500 cm-1, 1901 cm-1 (O-H….N, br), 3302 cm-1 (NH  amide), 
1708 cm-1 (C=O acid, s), 1625 cm-1 (C=O, amide, s). 
 
Synthesis of N,N'-bis(4-pyridinecarboxamide)-1,4-butane 
succinic acid (1:1), 12. N,N’-bis(4-pyridinecarboxamide)-1,4-
butane Ia (0.015 g, 0.053 mmol)  was dissolved in 4 mL of 
ethanol-nitromethane (1:1) to which a solution of succinic acid 
(0.006 g, 0.053 mmol) in  4 mL of ethanol-nitromethane (1:1) 
was added and allowed to stand at room temperature to undergo 
slow evaporation. Colorless needles were obtained after five 
days. Mp 227-229 oC; (ZnSe ATR crystal) υ 2504 cm-1, 1973 
cm-1 (OH…N, br), 3382 cm-1 (N-H amide), 1699 cm-1 (C=O, 
acid, s), 1625 cm-1 (C=O, amide, s). 
 
Synthesis of N,N'-bis(4-pyridinecarboxamide)-1,4-butane 
sebacic acid (1:1), 13. 
N,N’-bis(4-pyridinecarboxamide)-1,4-butane Ia (0.015 g, 0.053 
mmol) was dissolved in 4 mL of ethanol-nitromethane (1:1) to 
which sebacic acid (0.010 g, 0.053 mmol) in 4 mL of ethanol-
nitromethane (1:1) was added and allowed to stand at room 
temperature to slowly evaporate. Colorless needles were 
obtained after thirteen days. M.p.: 187-189oC; (ZnSe ATR 
crystal) υ 2496 cm-1, 1913 cm-1 (O-H…N, br), 3188 cm-1 (N-H 
amide), 1697 cm-1 (C=O acid, s), 1605 cm-1 (C=O amide, s). 
 
Synthesis of N,N'-bis(4-pyridinecarboxamide)-1,4-butane 
dodecanedioic acid (1:1), 14. 
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N,N’-bis(4-pyridinecarboxamide)-1,4-butane Ia (0.015 g, 0.053 
mmol) was dissolved in 4 mL of ethanol-nitromethane (1:1) to 
which dodecanedioic acid (0.012 g, 0.053 mmol) in 4 mL of 
ethanol-nitromethane (1:1) was added and allowed to stand at 
room temperature to slowly evaporate. Colorless prisms were 
obtained after five days. M.p.: 182-184 oC.  (ZnSe ATR crystal) 
υ 2500 cm-1, 1875 cm-1 (O-H…N, br), 3305 cm-1 (N-H amide), 
1710 cm-1 (C=O acid, s), 1626 cm-1 (C=O amide, s).  
 
Synthesis of N,N'-bis(4-pyridinecarboxamide)-1,8-octane 
dodecanedioic acid (1:1), 15.   
N,N’-bis(4-pyridinecarboxamide)-1,8-octane Ib (0.015 g, 
0.0423 mmol) was dissolved in 4 mL of ethanol-nitromethane 
(1:1) to which dodecanedioic acid (0.097g, 0.0423 mmol) in 4 
mL of ethanol-nitromethane (1:1) was added and allowed to 
stand at room temperature to evaporate. Colorless needles were 
obtained after ten days. M.p.: 154-156 oC.  (ZnSe ATR crystal) 
υ 2514 cm-1, 1900 cm-1 (O-H…N, br), 3326 cm-1 (N-H amide), 
1707 cm-1 (C=O acid, s), 1632 cm-1 (C=O amide, s).   
Solubility studies 
Preparation of co-crystals for solubility studies 
 Co-crystals of Ib and dicarboxylic acid (1:1 molar ratio) 
were prepared via a solvothermal method.18 Supersaturation of 
Ib and succinic acid was accomplished by cooling a solution of 
Ib (0.5551 g, 1.566 mmol) and succinic acid (0.1849, 1.566 
mmol) in 25.00 mL of ethanol from 40 ˚C to 25 oC. The solid 
phase was harvested by vacuum filtration and dried at room 
temperature (22-23 oC) on a Fisherbrand filter paper for 40 min 
to remove any adsorbed solvent. The solid obtained was 
confirmed to be a co-crystal by FT-IR spectroscopy; also the IR 
obtained matched the previous IR of crystals submitted for X-
ray analysis. Co-crystals were stored in a desiccator over 
anhydrous calcium sulfate. The remaining co-crystals were 
prepared and analyzed following the same procedure. 
 
Aqueous solubility of APIs and co-crystals 
 The solubility of Ib and its respective co-crystals in water 
was determined from undersaturation by adding excess co-
crystal solid phase in water. The suspensions were stirred with 
magnetic stirrers in a sealed 500 mL flask at constant 
temperature (25 ± 0.5 oC) maintained with a water bath. 
Samples were drawn at various time intervals over 72 hrs and 
filtered. Samples were diluted with the same solvent in which 
the solubility analysis was performed. The solutions 
equilibrated within 48 hrs and average sample concentration 
differed by <3% at 24 hrs and 48 hrs. Concentrations of 
samples were obtained measuring the absorbance of Ib at λmax 
= 234.8 nm. All UV-Vis measurements were carried out on a 
Shimadzu UV-1650 PC. 
 
Description of crystal structures of co-crystals 1-11. 
Co-crystallization reactions between Ia, Ib, II and even-chain 
aliphatic dicarboxylic acids were carried out, and IR 
spectroscopy was used to screen all of the resulting solids for 
co-crystal formation. We were also able to grow crystals 
suitable for single-crystal X-ray diffraction for eleven products.  
The crystal structures of 1 and 2 show that the API and the 
diacids are present in a 1:1 ratio, with hydrogen bonds between 
the pyridine nitrogen and the dicarboxylic acid in both 
structures, Table 1. The O-H…N interactions result in infinite 
1-D chains, which are subsequently assembled into a 2-D sheet  
via the aid of amide…amide (N-H…O) interactions, Figure 2 
and Figure 3, respectively. 
The four crystal structures containing Ib are very similar in that 
each asymmetric unit consists of one molecule of Ib and one 
molecule of the corresponding dicarboxylic acid. Again the 
acid…pyridine supramolecular synthon drives the co-crystal 
formation, Table 1, and the self-complementary amide…amide 
hydrogen bond produces a sheet-like architecture, Figures 4-5. 
Figure 2 2-D sheet in the crystal structure of 1, held together by O-
H…N and N-H…O interactions. 
Figure 3 2-D sheet in the crystal structure of 2 held together by O-
H…N and N-H…O interactions. 
Figure 4 2-D sheet in the crystal structure of 4, held together by O-
H…N and N-H…O interactions. 
All five co-crystals of II display a 1:1 stoichiometry, and in each 
case the COOH…N(py) interaction drives the assembly.  However, 
there is a slight difference to the way in which the chains are 
arranged in these five structures.  In 7, 8, 10 and 11, 1-D chains are 
cross-linked via amide…amide, N-H…O hydrogen bonds, resulting 
in 2-D corrugated sheets, Figs. 6-7, for two such examples. 
Figure 5 2-D sheet in the crystal structure of 5, held together by O-
H…N and N-H…O interactions 
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However, although the crystal structure of 9 contains 1-D chains as 
well as amide…amide homosynthons, the overall layer is much more 
planar, Figure 8, and more similar to the architectures that were 
found in the structures of 1-6.    
   
ARTICLE  Journal Name 
6 | J.  Name., 2012, 00, 1‐3  This journal is © The Royal Society of Chemistry 2012 
Table 1. Hydrogen-Bond Geometries for 1-11 
*x+1, y, z; **x, y-1, z; ***x-1, y, z 
 
 
 
 
Figure 6  2-D zig-zag layer in 7 held together via O-H…N and N-
H…O hydrogen bonds. 
 
 
Figure 7  2-D corrugated layer in the crystal structure of 10 
formed through O-H…N and N-H…O hydrogen bonds. 
 
Figure 8.  A flat layer in the crystal structure of 9.  This motif 
is the only structural outlier in the five structures with II. 
 
Addressing structural consistency 
   The intermolecular interactions observed in the series of co-
crystals are remarkably consistent. In all eleven cases the 
pyridine nitrogen…acid heterosynthon was detected through 
both IR spectroscopy and single-crystal X-ray diffraction. 
Furthermore, the amide…amide homosynthon was also 
observed in all eleven co-crystals reported herein.  In seven of 
the eleven structures, the outcome was a 2-D layered 
construction where the individual layers were flat (this was true 
for all structures from Ia and Ib, and one from II).  The 
remaining crystal structures (all with II) contained highly 
corrugated 2-D assemblies, even though the synthons were 
Compound D-H...A d(D-H)/Å d(H...A)/ Å d(D...A)/ Å <(DHA)/deg 
1 O(31)-H(31)…N(11) 0.908(14) 1.788(14) 2.6940(9) 175.0(13) 
 N(17)-H(17)…O(17)*** 0.864(13) 2.139(13) 2.9876(9) 167.1(12) 
      
2 O(31)-H(31)…N(11) 0.909(14) 1.756(16) 2.6942(11) 178.7(14) 
 N(17)-H(17)…O(17)*** 0.880(14) 2.130(14) 2.9920(11) 166.1(12) 
      
3 O(31)-H(31)…N(11) 0.896(19) 1.817(19) 2.7128(15) 178.3(18) 
 N(17)-H(17)…O(17)** 0.844(16) 2.150(15) 2.9834(14) 169.5(15) 
      
4 O(31)-H(31)…N(11) 0.925(15) 1.782(15) 2.7056(11) 176.3(18) 
 N(17)-H(17)…O(17)** 0.848(14) 2.170(14) 3.0039(12) 167.9(13) 
      
5 O(31)-H(31)…N(11) 0.905(18) 1.798(18) 2.7026(14) 177.21(17) 
 N(17)-H(17)…O(17)* 0.853(17) 2.173(17) 3.00067(14) 165.5(15) 
      
6 O(31)-H(31)…N(11) 0.96(2) 1.73(2) 2.6912(17) 178.6(18) 
 N(17)-H(17)…O(17)* 0.899(19) 2.125(19) 2.9984(16) 163.5(16) 
      
7 O(31A)-H(31A)…N(11) 0.84 1.81 2.6488(10) 176.8 
 O(31B)-H(31B)…N(11) 0.84 2.06 2.894(7) 173.6 
 N(17)-H(17)…O(17)*** 0.852(12) 2.089(12) 2.9244(9) 166.8(11) 
      
8 O(31)-H(31)…N(11) 1.010(17) 1.704(17) 2.7137(15) 177.2(15) 
 N(17)-H(17)…O(17)* 0.835(17) 2.110(18) 2.9394(14) 172.1(15) 
      
9 O(31)-H(31)…N(11) 1.00(3) 1.73(3) 2.728(2) 175(2) 
 N(17)-H(17)…O(17)* 0.80(2) 2.24(2) 3.021(2) 165.6(19) 
      
10 O(31)-H(31)…N(11) 0.935(19) 1.748(19) 2.6802(13) 175.0(15) 
 N(17)-H(17)…O(17)* 0.913(16) 1.997(16) 2.8953(12) 167.6(13) 
      
11 O(31)-H(31)…N(11) 0.862(19) 1.826(19) 2.6839(15) 173.7(17) 
 N(17)-H(17)…O(17)*** 0.851(18) 2.060(18) 2.8993(14) 169.1(15) 
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identical to the ones found in the seven structures with flat 
layers.  
 
Fine-tuning the melting behavior of Ia-b  
It has previously been shown that co-crystallization can be used 
as a tool for improving the thermal stability19 as well as other 
physicochemical properties4,5,6,7 of several APIs. With this in 
mind, and having achieved considerable structural consistency 
(no outliers with either Ia or Ib) we subsequently examined 
whether the melting behavior of co-crystals formed with Ia, Ib 
could be correlated with any molecular feature of the five even- 
numbered dicarboxylic acids. Melting points were recorded for 
all co-crystals of Ia and Ib, and plotted against the melting 
points of the corresponding pure acids, Figures 9-10. The data 
clearly show that the melting points of these five solids are 
directly related to the melting points of the pure acids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9  Melting points of co-crystals of Ia vs. melting points 
of corresponding diacids; where SUC=succinic; ADI=adipic; 
SUB=suberic; SEB=sebacic and DOD=dodecanedioic acid. 
 
The co-crystal in each series displays a higher melting point 
than the corresponding pure diacid; this is presumably because 
of the additional strong hydrogen bonds that take place between 
acid and pyridine combined with efficient close packing of the 
planar layers. Thus, in Ia, the highest-melting co-crystal 
contains the dicarboxylic acid with the highest melting point, 
and the lowest-melting acid produces the lowest-melting co-
crystal.   
 
 
 
 
 
 
 
Figure 10 Melting points of co-crystals of Ib vs. melting points of the 
corresponding diacids.  
These results demonstrate that it is possible to modulate the melting 
behavior of a given API in a highly predictable and controlled 
manner, over a significant range (184-229 oC; the melting point of 
the API itself is 230-232 oC). Likewise, Ib demonstrated similar 
trends with melting points of co-crystals ranging from 156-187 oC 
(the melting point of the API itself is 165-166 oC). 
Interestingly, there is also a connection between the density of 
the co-crystals and the density of the relevant acid, Fig. 11.  
The five co-crystals of II show a similar linear correlation with 
an R2-value of 0.93. 
 
 
 
Figure 11 Crystal densities of co-crystals of Ib vs. the densities of the 
corresponding diacids.   
 
  This again is likely due to the fact that there is considerable 
structural consistency within the crystal structures of Ib and II, 
and we may even begin to think about each supramolecular 
chain as an individual molecular species, the chemical 
composition of which is altered in a step-wise manner by 
adding two –CH2- groups from one molecule to the next.  
 
Additionally, the melting point alteration in this series 
constitutes a readily explainable change in the physical 
properties of a pure component series as a consequence of co-
crystal formation.  The change in chain-length of the API 
(butane vs. octane) has no effect on predictability, the same 
synthons as well as the overall structures are present in both 
series Ia and Ib. 
However, switching from a 4,4’ isomer to a 3,3’-isomer (as 
from I to II) does have a detrimental effect establishing a 
correlation between molecular structure and physical 
properties.  The relevant plot is shown in Figure 12, and it is 
clear that nothing can be inferred about bulk properties based 
upon molecular structure. 
This is of course not unexpected since we have lost the 
structural consistency in this series, whereas co-crystals of Ia/b 
all contained the same general features.   
Altering aqueous solubility 
 Although thermal properties are important, aqueous 
solubility is one of the key physicochemical parameters of a 
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drug substance that needs to be assessed early on in the drug 
discovery process and optimized in the latter formulation 
stages. The results show that the aqueous solubility of Ib can in 
fact be improved by a factor of 4.5 without altering the 
molecular structure of the API itself, Figure 13. Although the 
solubility of the co-crystals of Ib did not produce a linear 
correlation with the aliphatic even-chain dicarboxylic acids, as 
did the melting points, the trend in physicochemical properties 
of the co-crystals can certainly be rationalized in terms of the 
aqueous solubility of the dicarboxylic acids. The co-crystals of 
the less polar and more hydrophobic longer-chain diacids show 
a reduced aqueous solubility relative to that of the API itself. 
 
 
 
 
 
 
 
Figure 12 Melting points of co-crystals of II vs. melting point of the 
corresponding diacids.  
Furthermore, when comparing this result to our previously reported 
study on the solubility of a similar compound with a shorter 
methylene chain length,7 it is interesting to note that the solubility of 
the API with a longer methylene chain length is significantly lower 
than those with a shorter chain length. Moreover, a significant 
increase in solubility is observed upon co-crystallization when the 
solubility of the API itself is very poor. 
 
 
 
 
 
 
 
 
 
Figure 13    Aqueous solubility of Ib and five co-crystals thereof.  
 
Conclusions 
 We were able to show that Ia, Ib and II are capable of 
forming co-crystals with aliphatic even-chain dicarboxylic 
acids, where the driving force for co-crystal formation is the 
strong COOH….N(py) hydrogen bond. A high degree of 
structural consistency was found, which was reflected in a 
positive correlation between molecular characteristics and bulk 
physical properties. We were also able to show that the melting 
behaviour of Ia and Ib can be modulated in a predictable 
fashion without making or breaking covalent bonds.  
 However changing the geometry of the API changes both 
the packing motif and the melting behaviour as shown by the 
co-crystals of II. This provides us with additional information 
as to how changing carbon chain length and geometry will 
affect the structural and physical properties of a given 
compound.  It is clear that structural consistency is a 
requirement for being able to connect molecular shape/property 
to predictable physical properties of the corresponding bulk 
solids in a series of related compounds. 
 Although it is obvious that not every co-crystal will deliver 
an improvement in physicochemical properties relative to that 
of the active ingredient, we have shown that systematic changes 
to the molecular nature of the co-crystallizing agent combined 
with control over the way that the individual building blocks 
are organized within the crystalline lattice makes it possible to 
establish predictable links between molecular structure and 
macroscopic physical properties. In this context, co-crystals 
may therefore offer unique opportunities for developing new 
solid forms in which a variety of desired physical properties can 
be tuned in a predictable manner. 
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